Veradermics presents VDPHL01 data showing significant hair growth in two male pattern hair loss studies
MANE•Veradermics said VDPHL01 met both co-primary efficacy endpoints in two male pattern hair loss studies. Six-month target-area hair counts increased by 36.4 versus 6.6 with placebo in Study 304, and by 33.0 versus 7.3 in Study 302.
1. Study results
Veradermics said twice-daily VDPHL01 met both co-primary efficacy endpoints with high statistical significance in two registration-directed male pattern hair loss studies. Six-month target-area hair counts increased by 36.4 in Study 304, compared with 6.6 with placebo, and by 33.0 in Study 302, compared with 7.3 with placebo.
2. Patient reports and trial
Patient-reported improvement rates with twice-daily dosing were 68.7% in Study 304 and 62.9% in Study 302. Veradermics said its female Phase 2/3 trial is fully enrolled with 556 participants, with initial topline data expected in the first half of 2027.
